Cancer Epidemiology Biomarkers & Prevention, Vol 3, Issue 5 433-438, Copyright © 1994 by American Association for Cancer Research

ARTICLES

Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells

LJ Hixson, DS Alberts, M Krutzsch, J Einsphar, K Brendel, PH Gross, NS Paranka, M Baier, S Emerson and R Pamukcu
Department of Medicine, University of Arizona, Tucson 85724.

Several lines of evidence suggest that nonsteroidal antiinflammatory drugs may be effective in preventing colorectal cancer. These include animal experiments, case-control studies, and clinical experience with sulindac in promoting the regression of adenomatous colon polyps in adenomatous polyposis coli. We determined the antiproliferative activity of various nonsteroidal antiinflammatory drugs, including two sulindac derivatives, against human colon cancer cells in vitro. Ht-29, SW480, and DLD-1 cells were continuously incubated with serial drug dilutions for 6 days prior to fixation. Cell number was determined using the sulforhodamine B assay, and drug concentrations which inhibited cell growth by 50% were estimated for each agent by interpolation. All drugs exhibited antiproliferative activity against Ht-29 and DLD-1 cells, and most inhibited SW480 cells. For Ht-29 cells, the 50% inhibitory concentration varied from 55 microM for diclofenac to 2100 microM for 5-aminosalicylic acid, with three drug groups of high, intermediate, and low potency evident. Inhibition of cell growth by sulindac sulfide was reversible following drug removal. Nonsteroidal antiinflammatory drugs exert an antiproliferative effect against human colon cancer cells with a wide range of potencies. A cytostatic response was demonstrated with sulindac sulfide. These data further support the potential role of these agents for chemoprevention of colorectal neoplasia.

This article has been cited by other articles:

				E. Sagiv, U. Rozovski, D. Kazanov, E. Liberman, and N. Arber Gene Expression Analysis Proposes Alternative Pathways for the Mechanism by Which Celecoxib Selectively Inhibits the Growth of Transformed but not Normal Enterocytes Clin. Cancer Res., November 15, 2007; 13(22): 6807 - 6815. [Abstract] [Full Text] [PDF]

				F. G. Bottone Jr, J. M. Martinez, B. Alston-Mills, and T. E. Eling Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells Carcinogenesis, March 1, 2004; 25(3): 349 - 357. [Abstract] [Full Text] [PDF]

				G. Hawcroft, S. H. Gardner, and M. A. Hull Activation of Peroxisome Proliferator-Activated Receptor gamma Does Not Explain the Antiproliferative Activity of the Nonsteroidal Anti-Inflammatory Drug Indomethacin on Human Colorectal Cancer Cells J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 632 - 637. [Abstract] [Full Text] [PDF]

				A. Goel, D. K. Chang, L. Ricciardiello, C. Gasche, and C. R. Boland A Novel Mechanism for Aspirin-mediated Growth Inhibition of Human Colon Cancer Cells Clin. Cancer Res., January 1, 2003; 9(1): 383 - 390. [Abstract] [Full Text] [PDF]

				C Costa, R Soares, J S Reis-Filho, D Leitao, I Amendoeira, and F C Schmitt Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer J. Clin. Pathol., June 1, 2002; 55(6): 429 - 434. [Abstract] [Full Text] [PDF]

				G. A. Piazza, W. J. Thompson, R. Pamukcu, H. W. Alila, C. M. Whitehead, L. Liu, J. R. Fetter, W. E. Gresh Jr., A. J. Klein-Szanto, D. R. Farnell, et al. Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis Cancer Res., May 1, 2001; 61(10): 3961 - 3968. [Abstract] [Full Text]

				P. L. Rice, R. J. Goldberg, E. C. Ray, L. J. Driggers, and D. J. Ahnen Inhibition of Extracellular Signal-regulated Kinase 1/2 Phosphorylation and Induction of Apoptosis by Sulindac Metabolites Cancer Res., February 1, 2001; 61(4): 1541 - 1547. [Abstract] [Full Text]

				R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]

				S. R. Ritland, J. A. Leighton, R. E. Hirsch, J. D. Morrow, A. L. Weaver, and S. J. Gendler Evaluation of 5-Aminosalicylic Acid (5-ASA) for Cancer Chemoprevention: Lack of Efficacy against Nascent Adenomatous Polyps in the ApcMin Mouse Clin. Cancer Res., April 1, 1999; 5(4): 855 - 863. [Abstract] [Full Text] [PDF]

				H. Li, H. A.J. Schut, P. Conran, P. M. Kramer, R. A. Lubet, V. E. Steele, E. E. Hawk, G. J. Kelloff, and M. A. Pereira Prevention by aspirin and its combination with {alpha}-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis, March 1, 1999; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]